% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • audphil78 audphil78 Apr 5, 2013 4:34 AM Flag

    Cinryze Subcu Unlikely to enter market until 2016 or 2017...another mañana story!!

    The company was told by the FDA that the hurdles for approving its subcutaneous formulation of Cinryze would be higher than the current intravenous formulation. Any subcutaneous formulation of a C1 inhibitor is unlikely to enter the market until 2016 or 2017, making the threat of direct competition to ViroPharma's own plans for developing a subcutaneous version of Cinryze less of a threat than it appears on the surface.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.90-0.32(-3.13%)May 4 4:00 PMEDT